Bedrock Therapeutics

Bedrock Therapeutics is a private, pre-clinical stage biotech developing next-generation AAV-based gene therapies. Its core technology platform centers on engineering human-tropic and antibody-evading AAV capsids to improve targeting and overcome immune responses, alongside developing single-chain immune modulators (scIMs). The company's initial pipeline is focused on ophthalmic conditions, aiming to deliver safe, single-dose therapeutics. Led by a team of scientific co-founders and experienced executives, Bedrock is positioned to address key limitations in current gene therapy delivery and efficacy.

Two-pillar platform: 1) Engineered AAV capsids designed to be human-tropic and evade pre-existing neutralizing antibodies to improve gene delivery efficiency and patient eligibility. 2) Single-chain immune modulators (scIMs) to precisely control immune responses, potentially enhancing safety and efficacy of gene therapies or acting as standalone immunotherapies.

Bedrock operates in the highly competitive gene therapy space, competing with established players like Spark Therapeutics (Roche), Novartis, and Biogen, as well as numerous biotech startups. Its differentiation hinges on the potential superiority of its engineered capsids to overcome pre-existing immunity—a key bottleneck where many are actively competing.